Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Gross Profit (2016 - 2025)

Angiodynamics (ANGO) has disclosed Gross Profit for 16 consecutive years, with $44.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 12.22% year-over-year to $44.8 million, compared with a TTM value of $167.7 million through Nov 2025, up 11.07%, and an annual FY2025 reading of $157.7 million, up 1.94% over the prior year.
  • Gross Profit was $44.8 million for Q4 2025 at Angiodynamics, up from $41.9 million in the prior quarter.
  • Across five years, Gross Profit topped out at $46.5 million in Q2 2022 and bottomed at $35.9 million in Q1 2024.
  • Average Gross Profit over 5 years is $41.0 million, with a median of $40.4 million recorded in 2023.
  • The sharpest move saw Gross Profit soared 40.08% in 2021, then fell 16.92% in 2024.
  • Year by year, Gross Profit stood at $40.6 million in 2021, then rose by 11.15% to $45.1 million in 2022, then fell by 10.68% to $40.3 million in 2023, then decreased by 0.88% to $39.9 million in 2024, then grew by 12.22% to $44.8 million in 2025.
  • Business Quant data shows Gross Profit for ANGO at $44.8 million in Q4 2025, $41.9 million in Q3 2025, and $42.2 million in Q2 2025.